SeaStar Medical Estimates US Total Addressable Market For Its Proprietary, Patented Selective Cytopheretic Device In Five Clinical Indications Of $25B - $33B
SeaStar Medical Estimates US Total Addressable Market For Its Proprietary, Patented Selective Cytopheretic Device In Five Clinical Indications Of $25B - $33B
SeaStar Medical估計其專有的、專利的選擇性細胞治療設備在五個臨床適應症中的美國總可尋址市場爲250億至330億美元
The SCD has been awarded FDA Breakthrough Device Designation (BDD) in three of the five indications included in the chart above, namely adult AKI, hepatorenal syndrome and cardiorenal syndrome with LVAD. The SCD was also awarded BDD for chronic dialysis in November 2024.
SCD在上述表格中的五個適應症中的三個獲得了FDA突破性設備認證（BDD），即成年急性腎損傷、肝腎綜合症和心腎綜合症伴隨LVAD。SCD在2024年11月也獲得了慢性透析的BDD。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間